David R. Margrave Net Worth

Mr. David R. Margrave biography

David R. Margrave is the CFO & Sec. at Lantern Pharma.

What is the salary of Mr Margrave?

As the CFO & Sec. of Lantern Pharma, the total compensation of Mr Margrave at Lantern Pharma is $298,879. There are 1 executives at Lantern Pharma getting paid more, with Panna Sharma having the highest compensation of $750,492.

How old is Mr Margrave?

Mr Margrave is 60, he's been the CFO & Sec. of Lantern Pharma since . There are 1 older and 1 younger executives at Lantern Pharma. The oldest executive at Lantern Pharma Inc. is Dr. Kishor Gopaldas Bhatia Ph.D., 66, who is the Chief Scientific Officer & Scientific Consultant.

What's Mr Margrave's mailing address?

David's mailing address filed with the SEC is 1920 MCKINNEY AVENUE, 7TH FLOOR, , DALLAS, TX, 75201.

Insiders trading at Lantern Pharma

Over the last 4 years, insiders at Lantern Pharma have traded over $6,373,290 worth of Lantern Pharma stock and bought 10,000 units worth $150,000 . The most active insiders traders include Aaron G.L.Bios Fund I, Lpbi..., Leslie W.Cavu Management, L... und Maria Luisa Maccecchini. On average, Lantern Pharma executives and independent directors trade stock every 111 days with the average trade being worth of $423,325. The most recent stock trade was executed by Leslie W.Cavu Management, L... on 23 May 2024, trading 30,000 units of LTRN stock currently worth $189,000.

What does Lantern Pharma do?

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Lantern Pharma executives and stock owners

Lantern Pharma executives and other stock owners filed with the SEC include:

• Panna Sharma,
  Pres, CEO & Director
• David R. Margrave,
  CFO & Sec.
• Dr. Kishor Gopaldas Bhatia Ph.D.,
  Chief Scientific Officer & Scientific Consultant
• Nicole Leber,
  Fin. & Admin. Coordinator
• Dr. Peter L. Nara D.V.M., M.S., Ph.D.,
  Co-Founder & Advisor
• Park & Golf Ventures Ii, Ll...,
  
• Leslie W.Bios Equity Partne...,
  
• David S. Silberstein,
  Director
• Leslie W.Bp Directors, Lp B...,
  
• Aaron G.L.Bios Fund I, Lpbi...,
  
• Park & Golf Ventures Ii, Ll...,
  
• Arunkumar Asaithambi,
  
• Kishor G. Bhatia,
  Chief Scientific Officer
• Franklyn G Prendergast,
  Director
• D Jeffrey Keyser,
  Director
• Leslie W.Cavu Management, L...,
  
• David R. Margrave,
  Chief Financial Officer
• Panna Sharma,
  President and CEO
• Maria Luisa Maccecchini,
  Director